Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Arenare
Observed name:
Arenare, Laura
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0001-7100-4517
Observed ORCID:
0000-0001-7100-4517
OpenAlex ID:
A5123784658
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients
2026
·
Maria Lucia Iacovino
, Laura Arenare
, et al.
·
Lung Cancer
Figure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Supplementary Methods from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Data from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Validity and responsiveness of Patient-reported outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) in the ovarian cancer (OC) cohort of the FICOG VIP study.
2024
·
Arenare, Laura
·
Zenodo (CERN European Organization for Nuclear Research)
Dataset related to article "HR-SC - An academic-developed machine learning framework to classify HRD ovarian cancer patients and predict sensitivity to Olaparib"
2024
·
Beltrame, Luca
, Mannarino, Laura
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
Show more works
View as search
Works count:
14
Citation count:
H-index:
I10-index:
Year
Topic
Type